• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Katie Pfaff

Katie Pfaff

katie.pfaff@clarivate.com
Articles

ARTICLES

Dia to collaborate with Google Cloud to deliver automated ultrasound analysis

March 9, 2018
By Katie Pfaff
Dia Imaging Analysis Ltd. has inked a collaboration deal with Google Cloud to increase access to its automated ultrasound analysis tools. The agreement will allow practitioners to access Dia's software tools to analyze ultrasound images anywhere they can reach Google Cloud, bringing decision support to varied clinical or remote locations.
Read More

Orthofix secures FDA and CE mark approvals for its new Physiostim bone growth device

March 8, 2018
By Katie Pfaff
Orthofix International NV has won FDA approval and CE mark for its Physiostim bone growth stimulators to spur healing in extremity nonunion fractures. Physiostim's noninvasive pulsed electromagnetic field (PEMF) treatment has expanded treatment possibilities for patients with bone fractures that have not yet healed.
Read More

23andme wins FDA nod for BRCA gene report

March 7, 2018
By Katie Pfaff
The FDA has granted de novo approval to 23andme Inc. for its report on BRCA1 and BRCA2 risk for developing breast, prostate or ovarian cancer. The direct-to-consumer (DTC) saliva test can provide insight on three genetic mutations linked to the cancers, most commonly found in patients of Eastern European, or Ashkenazi Jewish heritage, which account for a relatively small portion of patients. There are more than 1,000 mutations of the BRCA gene, and the test is not intended to diagnose or rule out the presence of mutation, or increased risk of the particular cancers due to other factors.
Read More

Boston Scientific acquires endoscopic coagulation device maker Emcision

March 6, 2018
By Katie Pfaff
Boston Scientific Corp. has acquired private company Emcision Ltd., bringing the firm's Habib EndoHPB probe under its endoscopy division. The Habib endoscopic bipolar radiofrequency device is used to coagulate tissue in the gastrointestinal tract (GI) in treatment of patients with pancreaticobiliary cancers. Financial details of the transaction were not disclosed.
Read More

Stimguard set to study its tibial nerve OAB system against Medtronic's Interstim device

March 5, 2018
By Katie Pfaff
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary incontinence from over active bladder (OAB) not controlled by medication, following FDA approval of the trial with an investigational device exemption (IDE). Privately held Stimguard's device can be implanted in a physician's office with ultrasound guidance, avoiding a surgical procedure and general anesthesia required for the sacral device.
Read More

Idx finds success with pivotal trial of AI diabetic retinopathy test

March 2, 2018
By Katie Pfaff
Private diagnostics company Idx LLC reported its artificial intelligence (AI) system to detect diabetic retinopathy (DR) has met pivotal trial endpoints to assess patients for the disease in primary care. The 900-patient trial indicated the company's system, Idx-DR, is able to determine, within a few minutes, the presence of diabetic retinopathy among diabetic patients during a physician office appointment. The FDA granted breakthrough device designation and expedited review to the company earlier this month; the device has been under review since the start of 2018 with anticipated approval later in the year.
Read More

Abbott enters agreement with Surmodics to market its Surveil drug coated balloon

Feb. 28, 2018
By Katie Pfaff
Abbott Laboratories has inked a deal with Surmodics Inc. to collaboratively develop, trial and seek EU and U.S. approval for the Surveil drug coated balloon (DCB) in treatment of superficial femoral artery. Abbott will obtain exclusive global commercialization rights for Surveil under the agreement, which includes a $25 million initial payment to Surmodics and $67 million in potential milestone payments. Surveil is being assessed in a U.S. pivotal, randomized trial, TRANSCEND.
Read More

Reva wins CE mark for thinner bioresorbable scaffold, completes first surgical implantation

Feb. 27, 2018
By Katie Pfaff
Reva Medical Inc. has secured early CE mark and clinical implant of its 2.5 millimeter Fantom Encore bioresorbable scaffold, bringing a slimmed down version of its Fantom device to the European market. The first surgical implantation of the sirolimus-releasing scaffold with a 95 micron strut profile was completed at Universitätsklinikum Schleswig-Holstein in Kiel, Germany. Fantom Encore is X-ray visible, and uses Reva's Tyrocore polymer.
Read More

Diacarta earns $45M series B for its liquid biopsy cancer platform

Feb. 27, 2018
By Katie Pfaff
Molecular diagnostics company Diacarta Ltd. raised $45 million in its most recent series B funding, and will apply the capital to expand its liquid biopsy cancer detection platform. The cash flow will be used toward Diacarta's XNA technology platform to detect cancer at an early stage, and to expand globally.
Read More

Molecular diagnostics company Diacarta earns $45M series B for liquid biopsy cancer platform

Feb. 26, 2018
By Katie Pfaff
Molecular diagnostics company Diacarta Ltd. raised $45 million in its most recent series B funding and will apply the capital to expand its liquid biopsy cancer detection platform. The cash flow will be used toward Diacarta's XNA technology platform to detect cancer at an early stage and to expand globally. The round was led by Fortune Fountain Capital and included Good Health Capital. The company closed an $8 million series A funding in January 2015.
Read More
View All Articles by Katie Pfaff

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 12, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • Stacks of coins separated by a crack

    Filling the NIH funding gap to protect biopharma research

    BioWorld
    The Trump administration’s broad slash to university research budgets raises pertinent questions over impacts to the biopharma ecosystem, specifically how a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe